Ra Pharma doses first patient in pivotal Phase 3 myasthenia gravis study

Ra Pharmaceuticals (NASDAQ:RARX) dosed the first patient in its RAISE study, a pivotal Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG).

gMG is a chronic autoimmune disease characterized by skeletal muscle weakness and fatigue that becomes increasingly severe with repeated use.

Zilucoplan is a macrocyclic peptide designed to mediate the complement system, a critical component of the immune system.

RAISE is expected to enroll some 130 gMG patients and is designed to evaluate the efficacy of a once-daily dose of zilucoplan versus placebo. The study’s primary endpoint is the change in the MG activities of daily living score from baseline to week 12. 

“In a Phase 2 clinical trial, zilucoplan achieved rapid, clinically meaningful, and statistically significant reductions in primary and key secondary efficacy endpoints, with a durable treatment effect that was sustained at 24 weeks for patients enrolled in the long-term extension study,” Dr. James Howard, professor of neuromuscular disease at the University of North Carolina School of Medicine, said in a statement.

Ra expects topline results from this study in early 2021.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.